News
EXINI executes agreement with INmune Bio for Phase I/II trial
CaRe PC is an open label Phase I/II trial that will test up to three doses of INKmune™ in men with mCRPC. INKmune™ is given as out-patient therapy via intravenous infusion three times in the first...
New version released of PYLARIFY AI® (aPROMISE)
We have now released a new version of PYLARIFY AI® for prostate cancer analysis. The new version include features such as: Parallel Study Review Select all suggested hotspots CT Measurement Tool...
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 EuropeanAssociation of Nuclear Medicine (EANM) Annual Meeting
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using PYLARIFY®...
EXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.
Under the terms of the agreement, EXINI’s deep learning platform will be tailored to meet the specific needs of the European market. The clinical value proposition of the platform is to increase the...
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting
PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting with PYLARIFY AI on PSMA PET/CT images, including those...
EXINI Executes Agreement with Siemens Healthineers for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
As of November 2022, EXINI has entered into an agreement with Siemens Healthineers to integrate its artificial intelligence (AI) enabled software as a medical devices – aPROMISE™ (automated PROstate...
EXINI Executes Agreement with Bayer AG for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
As of November 2022, EXINI has entered into an agreement with Bayer AG to integrate its artificial intelligence (AI) enabled software as a medical devices – aPROMISE™ (automated PROstate Cancer...
EXINI Diagnostics AB (EXINI) collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC)
EXINI has entered into a collaboration with the PCCTC to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer. The PCCTC is a premier multicenter clinical research...
EXINI’s Artificial Intelligence enabled product received FDA clearance on GE Healthcare’s XELERIS platform
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the use of EXINI’s artificial intelligence enabled automated bone scan index (aBSI) on GE Healthcare’s Xeleris platform....